Forxiga CKD Japan Post-Marketing Surveillance (PMS)

Forxiga Tablets 5mg, 10mgGeneral Drug Use-Results Study n in Chronic Kidney Disease (CKD) Patients

To capture safety when Forxige is administrated to CKD patients in the real world setting

The purpose of the study is to review the following points during use of Forxiga Tablets (hereinafter referred to as Forxiga) in the real world setting after launch for treatment of CKD.

1. ADRs which are unexpected from the precautions for use in our JPI
2. Understanding of incidence of ADRs during use of Forxiga in the real world setting
3. Factors (ie demography, treatment) possibly having an impact on the safety.

Inclusion Criteria:

• Patients with CKD except for dialysis and/or renal failure chronic

Exclusion Criteria:

• None